Targeted therapy in advanced non-small cell lung cancer: current advances and future trends
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeted therapy in advanced non-small cell lung cancer: current advances and future trends
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 14, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-07-08
DOI
10.1186/s13045-021-01121-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Olmutinib in T790M‐positive non–small cell lung cancer after failure of first‐line epidermal growth factor receptor‐tyrosine kinase inhibitor therapy: A global, phase 2 study
- (2021) Keunchil Park et al. CANCER
- Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor
- (2021) Hiroaki Akamatsu et al. JAMA Oncology
- P37.30 Prevalence of Actionable Mutations among Indian Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review
- (2021) R. Raman et al. Journal of Thoracic Oncology
- BOS172738, a highly potent and selective RET inhibitor, for the treatment of RET-altered tumors including RET-fusion+ NSCLC and RET-mutant MTC: Phase 1 study results.
- (2021) Patrick Schoffski et al. JOURNAL OF CLINICAL ONCOLOGY
- Taletrectinib (AB-106; DS-6051b) in metastatic non-small cell lung cancer (NSCLC) patients with ROS1 fusion: Preliminary results of TRUST.
- (2021) Caicun Zhou et al. JOURNAL OF CLINICAL ONCOLOGY
- Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations.
- (2021) James Chih-Hsin Yang et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated overall efficacy and safety of selpercatinib in patients (pts) with RET fusion+ non-small cell lung cancer (NSCLC).
- (2021) Benjamin Besse et al. JOURNAL OF CLINICAL ONCOLOGY
- First-time in-human study of VMD-928, an oral allosteric TrkA selective inhibitor targeting TrkA protein overexpression, in patients with solid tumors or lymphoma.
- (2021) Vincent Chung et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and preliminary efficacy from the phase 1 portion of MasterKey-01: A First-in-human dose-escalation study to determine the recommended phase 2 dose (RP2D), pharmacokinetics (PK) and preliminary antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients (pts) with advanced solid malignancies.
- (2021) Alison M. Schram et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 1b, open-label, single-arm study of cofetuzumab pelidotin (a PTK7-targeting antibody-drug conjugate) in patients with PTK7-expressing, recurrent non-small cell lung cancer (NSCLC).
- (2021) Eric S. Schaefer et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 insertion mutations (Ins20).
- (2021) Zofia Piotrowska et al. JOURNAL OF CLINICAL ONCOLOGY
- Tepotinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) with MET amplification (METamp).
- (2021) Xiuning Le et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and efficacy of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer: Update from the ARROW trial.
- (2021) Giuseppe Curigliano et al. JOURNAL OF CLINICAL ONCOLOGY
- Capmatinib in MET exon 14-mutated, advanced NSCLC: Updated results from the GEOMETRY mono-1 study.
- (2021) Juergen Wolf et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination of trastuzumab, pertuzumab and docetaxel in patients with advanced non-small cell lung cancer (NSCLC) harboring HER2 mutation: Final results from the IFCT-1703 R2D2 trial.
- (2021) Julien Mazieres et al. JOURNAL OF CLINICAL ONCOLOGY
- KRYSTAL-12: A randomized phase 3 study of adagrasib (MRTX849) versus docetaxel in patients (pts) with previously treated non-small-cell lung cancer (NSCLC) with KRASG12C mutation.
- (2021) Tony S. K. Mok et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized, phase 3 study of datopotamab deruxtecan (Dato-DXd; DS-1062) versus docetaxel in previously treated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (TROPION-Lung01).
- (2021) Kiyotaka Yoh et al. JOURNAL OF CLINICAL ONCOLOGY
- CNS activity of poziotinib in NSCLC with exon 20 insertion mutations.
- (2021) Xiuning Le et al. JOURNAL OF CLINICAL ONCOLOGY
- Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study.
- (2021) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall survival and exploratory subgroup analyses from the phase 2 CodeBreaK 100 trial evaluating sotorasib in pretreated KRAS p.G12C mutated non-small cell lung cancer.
- (2021) Ferdinandos Skoulidis et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II two-arm study of tepotinib plus osimertinib in patients with EGFR-mutant NSCLC and acquired resistance to first-line osimertinib due to MET amplification: INSIGHT 2.
- (2021) Viola Weijia Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Intracranial activity of tepotinib in patients (pts) with MET exon 14 (METex14) skipping NSCLC enrolled in VISION.
- (2021) Jyoti D. Patel et al. JOURNAL OF CLINICAL ONCOLOGY
- Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response.
- (2021) Joshua Bauml et al. JOURNAL OF CLINICAL ONCOLOGY
- A first-in-human phase 1 study of a novel PARP7 inhibitor RBN-2397 in patients with advanced solid tumors.
- (2021) Gerald Steven Falchook et al. JOURNAL OF CLINICAL ONCOLOGY
- Sotorasib for Lung Cancers with KRAS p.G12C Mutation
- (2021) Ferdinandos Skoulidis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
- (2020) David S Hong et al. LANCET ONCOLOGY
- Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
- (2020) Lecia V Sequist et al. LANCET ONCOLOGY
- Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study
- (2020) Daniel S-W Tan et al. Lancet Respiratory Medicine
- Frequency of anaplastic lymphoma kinase rearrangements in Moroccan patients with non small cell lung cancer: a multi-institutional national retrospective study
- (2020) Hind El yacoubi et al. BMC CANCER
- Capmatinib in patients with high-level MET-amplified advanced non–small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study.
- (2020) Juergen Wolf et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of the antibody-drug conjugate (ADC) SAR408701 in patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5).
- (2020) Anas Gazzah et al. JOURNAL OF CLINICAL ONCOLOGY
- Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC).
- (2020) Keunchil Park et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and preliminary clinical activity of the MET antibody mixture, Sym015 in advanced non-small cell lung cancer (NSCLC) patients with MET amplification/exon 14 deletion (METAmp/Ex14∆).
- (2020) D. Ross Camidge et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II study of TAK228 in patients with advanced non-small cell lung cancer (NSCLC) harboring NFE2L2 and KEAP1 mutations.
- (2020) Paul K. Paik et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01.
- (2020) Egbert F. Smit et al. JOURNAL OF CLINICAL ONCOLOGY
- Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC).
- (2020) Justin F. Gainor et al. JOURNAL OF CLINICAL ONCOLOGY
- Nazartinib (EGF816) in patients with treatment-naïve EGFR-mutant non-small cell lung cancer (NSCLC): Updated phase II results.
- (2020) Daniel Shao-Weng Tan et al. JOURNAL OF CLINICAL ONCOLOGY
- SAF-189s in previously treated patients with advanced ALK-rearranged non-small cell lung cancer (NSCLC): Results from the dose-finding portion in a single-arm, first-in-human phase I/II study.
- (2020) Jin-Ji Yang et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I study to evaluate safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TQ-B3101.
- (2020) Yong Fang et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I/II study of REGN5093, a MET x MET bispecific antibody, in patients with MET-altered advanced non-small cell lung cancer (NSCLC).
- (2020) Tracey Rowlands et al. JOURNAL OF CLINICAL ONCOLOGY
- TRIDENT-1: A global, multicenter, open-label Phase II study investigating the activity of repotrectinib in advanced solid tumors harboring ROS1 or NTRK1-3 rearrangements.
- (2020) Robert Charles Doebele et al. JOURNAL OF CLINICAL ONCOLOGY
- The next-generation RET inhibitor TPX-0046 is active in drug-resistant and naïve RET-driven cancer models.
- (2020) Alexander E. Drilon et al. JOURNAL OF CLINICAL ONCOLOGY
- Preliminary dose escalation results from a phase I/II, first-in-human study of MGC018 (anti-B7-H3 antibody-drug conjugate) in patients with advanced solid tumors.
- (2020) John D. Powderly et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of alflutinib (AST2818) in patients with T790M mutation-positive NSCLC: A phase IIb multicenter single-arm study.
- (2020) Yuankai Shi et al. JOURNAL OF CLINICAL ONCOLOGY
- Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
- (2020) Paul K. Paik et al. NEW ENGLAND JOURNAL OF MEDICINE
- The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping
- (2020) Ravi Salgia et al. CANCER TREATMENT REVIEWS
- Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
- (2020) D. Ross Camidge et al. JOURNAL OF CLINICAL ONCOLOGY
- The Effect of Advances in Lung-Cancer Treatment on Population Mortality
- (2020) Nadia Howlader et al. NEW ENGLAND JOURNAL OF MEDICINE
- 1296P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC
- (2020) S.S. Schalm et al. ANNALS OF ONCOLOGY
- LBA61 First analysis of RAIN-701: Study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion, HER2-activating mutations & other solid tumours with NRG1/ERBB gene fusions
- (2020) S.V. Liu et al. ANNALS OF ONCOLOGY
- Phase 1 Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-Positive EGFR-Mutant Non-Small Cell Lung Cancer
- (2020) Helena A. Yu et al. CLINICAL CANCER RESEARCH
- KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation
- (2020) P.A. Jänne et al. EUROPEAN JOURNAL OF CANCER
- Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer
- (2020) Matthew J. LaMarche et al. JOURNAL OF MEDICINAL CHEMISTRY
- ID:1882 Phase III Randomized Study of Ensartinib vs Crizotinib in Anaplastic Lymphoma Kinase (ALK) POSITIVE NSCLC Patients: eXalt3
- (2020) G. Selvaggi et al. Journal of Thoracic Oncology
- Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer
- (2020) Jürgen Wolf et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
- (2020) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
- (2020) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer
- (2019) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I/II multiple expansion cohort trial of MRTX849 in patients with advanced solid tumors with KRAS G12C mutation.
- (2019) Kyriakos P. Papadopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- A multicenter, open label, randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer: TORG1833.
- (2019) Yoshiro Nakahara et al. JOURNAL OF CLINICAL ONCOLOGY
- Capmatinib for the treatment of non-small cell lung cancer
- (2019) Johan Filip Vansteenkiste et al. Expert Review of Anticancer Therapy
- P1.01-89 A Multicenter Phase 1/2a Trial of CLN-081 in NSCLC with EGFR Exon 20 Insertion Mutations
- (2019) Z. Piotrowska et al. Journal of Thoracic Oncology
- Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1–2 study
- (2019) Myung-Ju Ahn et al. LANCET ONCOLOGY
- Entrectinib for ROS1 fusion-positive NSCLC and NTRK fusion-positive solid tumours
- (2019) Ulrik Lassen LANCET ONCOLOGY
- Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
- (2019) Alexander Drilon et al. LANCET ONCOLOGY
- Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Kazuhiko Nakagawa et al. LANCET ONCOLOGY
- BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers
- (2018) Jaquelyn N. Sanchez et al. DRUGS
- Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial
- (2018) Bob T. Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Brief Report: Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients with RET -Rearranged Lung Cancers
- (2018) Alexander Drilon et al. Journal of Thoracic Oncology
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase I study of LXH254 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.
- (2018) Filip Janku et al. JOURNAL OF CLINICAL ONCOLOGY
- PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in patients (pts) with advanced solid tumors: Results of a phase I dose escalation and expansion study.
- (2018) Jasgit C. Sachdev et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy
- (2018) Tatsuya Nagano et al. Cells
- MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values
- (2017) Geun Dong Lee et al. Journal of Thoracic Oncology
- Dabrafenib plus trametinib in patients with previously untreated BRAF V600E -mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
- (2017) David Planchard et al. LANCET ONCOLOGY
- A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions
- (2017) Marc Damelin et al. Science Translational Medicine
- Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
- (2017) Emmet J. Jordan et al. Cancer Discovery
- AACR Project GENIE: Powering Precision Medicine through an International Consortium
- (2017) Cancer Discovery
- Clinicopathologic characteristics and outcomes of Chinese patients with non-small-cell lung cancer andBRAFmutation
- (2017) Xi Ding et al. Cancer Medicine
- An overview of rapamycin: from discovery to future perspectives
- (2016) Young Ji Yoo et al. JOURNAL OF INDUSTRIAL MICROBIOLOGY & BIOTECHNOLOGY
- Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor
- (2016) Jorge Garcia Fortanet et al. JOURNAL OF MEDICINAL CHEMISTRY
- Somatic mutation analysis of KRAS, BRAF, HER2 and PTEN in EGFR mutation-negative non-small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel deletion in HER2 gene from Indian patients
- (2016) Sangeet Bhaumik et al. MEDICAL ONCOLOGY
- The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma
- (2016) Anna Biernacka et al. Cancer Genetics
- Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer
- (2015) Anna F. Farago et al. Journal of Thoracic Oncology
- Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience
- (2015) Lynette M. Sholl et al. Journal of Thoracic Oncology
- PIK3CA mutations in non-small cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and incidence of prior malignancies
- (2015) Matthias Scheffler et al. Oncotarget
- KRAS-G12C Mutation Is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma
- (2014) Ernest Nadal et al. Journal of Thoracic Oncology
- A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)
- (2014) Yuankai Shi et al. Journal of Thoracic Oncology
- Comprehensive molecular profiling of lung adenocarcinoma
- (2014) Eric A. Collisson et al. NATURE
- Novel Targets in Non-Small Cell Lung Cancer: ROS1 and RET Fusions
- (2013) J. F. Gainor et al. ONCOLOGIST
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
- (2012) Kristin Bergethon et al. JOURNAL OF CLINICAL ONCOLOGY
- Kinase-driven pathways of EGFR in lung carcinomas: perspectives on targeting therapy
- (2010) Yoh Dobashi Frontiers in Bioscience-Landmark
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- (2009) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas
- (2008) Yoh Dobashi et al. CANCER
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started